Mechanisms of action and resistance of older and newer fluoroquinolones - PubMed (original) (raw)
Review
. 2000 Aug:31 Suppl 2:S24-8.
doi: 10.1086/314056.
Affiliations
- PMID: 10984324
- DOI: 10.1086/314056
Review
Mechanisms of action and resistance of older and newer fluoroquinolones
D C Hooper. Clin Infect Dis. 2000 Aug.
Abstract
The fluoroquinolones interact with 2 bacterial targets, the related enzymes DNA gyrase and topoisomerase IV, both of which are involved in DNA replication. Quinolones form complexes of these enzymes with DNA, complexes that block movement of the DNA-replication fork and thereby inhibit DNA replication. Many older quinolones differ in their relative activities against gyrase and topoisomerase IV in a bacterial cell, having greater potency against gyrase than against topoisomerase IV in many gram-negative bacteria and greater potency against topoisomerase IV than against gyrase in many gram-positive bacteria. Several newer quinolones appear to have more closely balanced activity against these enzymes. Resistance to fluoroquinolones occurs as a result of mutational amino acid substitutions in the subunits of the more sensitive (or primary-target) enzyme within the cell. If, however, both enzymes are similarly susceptible to a fluoroquinolone, then the level of resistance caused by a primary-target mutation may be low and may be limited by the sensitivity of the secondary target. Fluoroquinolones also differ in the extent to which common bacterial multidrug efflux pumps affect their activity, with some compounds being unaffected by resistance mechanisms because of overexpression of such pumps. Newer fluoroquinolone interaction with dual targets and avoidance of efflux-resistance mechanisms may each contribute to the lower frequencies of selection of resistant mutants in the laboratory.
Similar articles
- Mechanisms of resistance to fluoroquinolones.
Rattan A. Rattan A. Natl Med J India. 1999 Jul-Aug;12(4):162-4. Natl Med J India. 1999. PMID: 10573971 Review. - Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
Schmitz FJ, Higgins PG, Mayer S, Fluit AC, Dalhoff A. Schmitz FJ, et al. Eur J Clin Microbiol Infect Dis. 2002 Sep;21(9):647-59. doi: 10.1007/s10096-002-0788-z. Epub 2002 Sep 7. Eur J Clin Microbiol Infect Dis. 2002. PMID: 12373497 Review. - Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B. Roychoudhury S, et al. Antimicrob Agents Chemother. 2001 Apr;45(4):1115-20. doi: 10.1128/AAC.45.4.1115-1120.2001. Antimicrob Agents Chemother. 2001. PMID: 11257024 Free PMC article. - Mechanisms of resistance to quinolones.
Jacoby GA. Jacoby GA. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S120-6. doi: 10.1086/428052. Clin Infect Dis. 2005. PMID: 15942878 Review. - [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G, Martínez-Toldos MC, Alonso Manzanares MA, Gutiérrez Zufiaurre MN, Martínez-Andrés JA, Muñoz Bellido JL, García-Rodríguez JA, Segovia Hernández M. Yagüe Guirao G, et al. Rev Esp Quimioter. 2000 Sep;13(3):271-5. Rev Esp Quimioter. 2000. PMID: 11086276 Spanish.
Cited by
- Comparative genomics analysis of the multidrug-resistant Aeromonas hydrophila MX16A providing insights into antibiotic resistance genes.
Guo Y, Zeng C, Ma C, Cai H, Jiang X, Zhai S, Xu X, Lin M. Guo Y, et al. Front Cell Infect Microbiol. 2022 Nov 3;12:1042350. doi: 10.3389/fcimb.2022.1042350. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36405966 Free PMC article. - Chemical space of Escherichia coli dihydrofolate reductase inhibitors: New approaches for discovering novel drugs for old bugs.
Srinivasan B, Tonddast-Navaei S, Roy A, Zhou H, Skolnick J. Srinivasan B, et al. Med Res Rev. 2019 Mar;39(2):684-705. doi: 10.1002/med.21538. Epub 2018 Sep 7. Med Res Rev. 2019. PMID: 30192413 Free PMC article. Review. - Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor.
Hegde SS, Vetting MW, Mitchenall LA, Maxwell A, Blanchard JS. Hegde SS, et al. Antimicrob Agents Chemother. 2011 Jan;55(1):110-7. doi: 10.1128/AAC.01158-10. Epub 2010 Oct 11. Antimicrob Agents Chemother. 2011. PMID: 20937785 Free PMC article. - Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ. Cheng J, et al. Antimicrob Agents Chemother. 2007 Jul;51(7):2445-53. doi: 10.1128/AAC.00158-07. Epub 2007 May 14. Antimicrob Agents Chemother. 2007. PMID: 17502409 Free PMC article. - Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.
Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C. Arjyal A, et al. Lancet Infect Dis. 2011 Jun;11(6):445-54. doi: 10.1016/S1473-3099(11)70089-5. Epub 2011 Apr 29. Lancet Infect Dis. 2011. PMID: 21531174 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources